Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E131.05 EPS (ttm)4.02 Insider Own0.30% Shs Outstand103.69M Perf Week11.35%
Market Cap54.63B Forward P/E35.36 EPS next Y14.90 Insider Trans-24.03% Shs Float76.44M Perf Month-1.21%
Income460.60M PEG5.80 EPS next Q3.14 Inst Own73.70% Short Float4.57% Perf Quarter-2.96%
Sales3.40B P/S16.08 EPS this Y-19.40% Inst Trans-0.04% Short Ratio4.05 Perf Half Y15.77%
Book/sh32.45 P/B16.24 EPS next Y21.36% ROA11.30% Target Price617.05 Perf Year53.37%
Cash/sh5.83 P/C90.40 EPS next 5Y22.58% ROE16.10% 52W Range320.06 - 605.93 Perf YTD28.42%
Dividend- P/FCF- EPS past 5Y41.20% ROI12.50% 52W High-13.05% Beta0.85
Dividend %- Quick Ratio3.60 Sales past 5Y49.40% Gross Margin91.50% 52W Low64.60% ATR24.73
Employees2925 Current Ratio3.80 Sales Q/Q50.00% Oper. Margin31.20% RSI (14)55.29 Volatility5.18% 5.04%
OptionableYes Debt/Eq0.12 EPS Q/Q98.80% Profit Margin13.60% Rel Volume1.53 Prev Close503.92
ShortableYes LT Debt/Eq0.12 EarningsNov 04 BMO Payout0.00% Avg Volume861.45K Price526.83
Recom2.10 SMA204.73% SMA50-0.43% SMA2009.28% Volume1,304,100 Change4.55%
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Sep-01-15Initiated Raymond James Outperform $615
Aug-31-15Downgrade Chardan Capital Markets Buy → Neutral $565
Aug-10-15Reiterated ROTH Capital Neutral $495 → $527
Aug-06-15Reiterated Argus Buy $560 → $660
Aug-05-15Reiterated UBS Sell $500 → $565
Aug-05-15Reiterated RBC Capital Mkts Outperform $570 → $665
Aug-05-15Reiterated Canaccord Genuity Buy $600 → $700
Aug-05-15Reiterated Barclays Equal Weight $460 → $595
Aug-04-15Reiterated Brean Capital Buy $525 → $659
Aug-03-15Reiterated Leerink Partners Outperform $559 → $630
Jul-27-15Reiterated RBC Capital Mkts Outperform $560 → $570
Jul-22-15Initiated Northland Capital Market Perform $560
Jul-20-15Reiterated RBC Capital Mkts Outperform $550 → $560
Jul-13-15Reiterated Deutsche Bank Buy $455 → $650
Jun-15-15Reiterated RBC Capital Mkts Outperform $543 → $550
Jun-10-15Reiterated Chardan Capital Markets Buy $560 → $565
May-20-15Reiterated Canaccord Genuity Buy $525 → $600
May-20-15Reiterated Argus Buy $500 → $560
May-19-15Reiterated Brean Capital Buy $507 → $525
Oct-12-15 08:06PM  Merck cholesterol drug's odds dim after Lilly failure
07:00PM  Cramer: Buy these stocks for the rest of 2015
04:31PM  Indexes Close Up Across The Board; Facebook Gains, But Twitter Falls at Investor's Business Daily
04:15PM  Energy Sector Retreated while Healthcare Sector Led on October 9
03:40PM  Winners and Losers of Eli Lilly's CETP Drug Failure at Motley Fool
03:06PM  4 Unusual-Volume Stocks to Trade for Breakouts at TheStreet
02:07PM  Lilly halts heart drug development
01:44PM  Stocks Near Flatline; Bad News for Lilly Is Good News For Regeneron at Investor's Business Daily
12:54PM  Regeneron Stock Pops But Hits Resistance At 50-Day
11:18AM  Lilly's Moat Still Intact After Halting Heart Drug Study at Morningstar
11:06AM  Lilly Loses Its Bloom; Amgen, Regeneron Blossom at
10:46AM  Jim Cramer -- Regeneron's Rally Is Going to Boost Biotechs at TheStreet
10:29AM  Stocks Open With Little Direction; NetEase Gains at Investor's Business Daily
10:20AM  Lilly's pain is Amgen, Regeneron and Esperion's gain at MarketWatch
09:24AM  Cramer's Mad Dash: REGN & AMGN
Oct-09-15 10:05AM  UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings at 24/7 Wall St.
Oct-08-15 10:13AM  The FDA Approved Mercks Drug Keytruda for Lung Cancer Treatment
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie
09:30AM  Regeneron to Report Third Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2015 PR Newswire
Oct-07-15 03:10PM  Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay +5.64%
12:02PM  Cholesterol Busters Will Be Cheaper but Remain Top Sellers at Motley Fool
11:35AM  Regeneron, Amgen Up As PCSK9s Gain Key Coverage at Investor's Business Daily
10:02AM  Are Cholesterol Drugs In For Another Revolution? at Investor's Business Daily
Oct-06-15 05:10PM  Express Scripts Says It Will Save America Money On New Cholesterol Drugs, But Its Math Doesn't Check Out at Forbes
05:00PM  How Express Scripts plans to cover a $14,000 drug at CNBC
05:00PM  Express Scripts sees $750 mln in spending on new cholesterol drugs
04:48PM  Gilead, Biotechs Were TPP Losers; Boeing Is Upbeat at Investor's Business Daily
04:07PM  How to play the biotech index: Pro
01:17PM  Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line? at Motley Fool
12:44PM  Bluebird Bio: A Buying Opportunity in Biotech, says Morgan Stanley at
Oct-05-15 12:26PM  Biotech: 'Significant Absolute Upside' at
11:58AM  Biotech: Sentiment Still Tenuous? at
11:40AM  Merck's (MRK) Keytruda Gains FDA Nod for Label Expansion
Oct-02-15 04:15PM  Sanofi Opts into Alnylam's ALN-AT3 Hemophilia Program
04:10PM  BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
03:30PM  Bristol-Myers' Melanoma Combo Opdivo/Yervoy Gets FDA Nod
03:10PM  Sarepta Unveils New Phase IIb Eteplirsen Data, Shares Soar
03:00PM  Where's the Best Risk-Reward in Biotech? at
02:38PM  Facebook, Netflix Top Goldman Sachs' 2016 Growth List at Investor's Business Daily
01:50PM  Integra (IART) Hopeful on Spine Spin-Off amid Global Woes
12:28PM  Why Morgan Stanley Downgraded Gilead, Valeant & Regeneron at
10:24AM  Regeneron Downgraded At Morgan Stanley; Better Biotech Peer Plays Elsewhere
06:18AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Oct-01-15 04:05PM  Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia PR Newswire
10:27AM  Regeneron Pharmaceuticals, Inc. Earnings Q2, 2015
10:20AM  Jazz's Defibrotide under FDA Priority Review, Shares Up
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead, Biogen and Celgene
09:11AM  Chiasma (CHMA) Jumps: Stock Adds 5.6% in Session
Sep-30-15 04:10PM  Express Scripts says Praluent, Repatha will not be "budget busters" Reuters
09:30AM  The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals, Kindred Healthcare, BioTelemetry, LeMaitre Vascular and Envision Healthcare Holdings
Sep-29-15 08:27PM  Three Pharmas Highlight Contrasting Approaches To Product Innovation at Forbes
04:35PM  Alnylam's Extension Study on Patisiran Reveals Positive Data
04:30PM  Allergan (AGN) Projects Revenues to Surpass $8B in 2H15
03:27PM  Biotech creeps higher
03:21PM  Biotech Stocks Took a Beating on September 25
11:23AM  Biotech, CAT Weigh on US Stocks in Week Ended September 25
11:03AM  30 Stocks to Consider Heading into Earnings at
09:10AM  Regeneron Pharmaceuticals and Sanofi Grab Another Important Win at Motley Fool
09:08AM  Regeneron and Mylan End Up in Green for the Week
08:23AM  5 Overvalued Health Care Stocks to Sell Now at TheStreet
Sep-28-15 04:35PM  Regeneron/Sanofi's PCSK9 Inhibitor Praluent Approved in EU -7.48%
04:17PM  Despite EU OK, Regeneron Crumbles Below 200-Day
10:30AM  Biotech: Does Anyone Care That Fundamentals Remain Strong? at
01:00AM  Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union PR Newswire
Sep-25-15 04:45PM  KemPharm (KMPH) Updates on Abuse-Deterrent Opioid Drug -6.00%
03:07PM  Stock Market Gains Shrink; Will Regeneron Break 200-Day Line? at Investor's Business Daily
11:59AM  The Price War for New Cholesterol Drugs Is Heating Up at Motley Fool
Sep-24-15 05:16PM  BioMed Realty Trust REIT Looks For A Buyer at Investor's Business Daily
04:40PM  Conatus Reports Promising Phase II Data on Emricasan
01:08PM  As Major Indexes Swoon, Gold ETF Hits 4-Week High at Investor's Business Daily
10:39AM  Can Valeant Recover From Clinton Price Gouging Tweet?
09:02AM  Health-care stocks may be your best bet today at MarketWatch
08:30AM  Regeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement PR Newswire
Sep-23-15 07:13PM  Biotech ETFs Lose Steam, Extend Week's Losses at Investor's Business Daily
04:45PM  Heron's (HRTX) Post-Operative Pain Candidate Encourages
08:02AM  3 Tech Stocks Buck Midweek Meltdown
Sep-22-15 04:55PM  Inovio Gets Grant for Ebola Drugs, Regeneron Inks Deal
04:42PM  5 Biotech Stocks Hit Hard by Hillary Clinton's Tweet
03:49PM  Biotech: Reaction to Clinton Plan 'Premature' at
02:30PM  Amgen's 2018 Repatha Sales Estimates Hiked 60% at Investor's Business Daily
11:07AM  Regeneron and Amgen Pull Down Biotechnology
10:04AM  Amgen & Regeneron: No, Clinton Tweet Won't Kill Anti-Cholesterol Drugs at
09:06AM  Regenerons Performance through August 2015
07:04AM  Biogen Stock Rises 6.81% August 2531
Sep-21-15 06:41PM  Biotech Stocks Fall As Clinton Tweets On 'Price Gouging'
04:50PM  Merck Reports Encouraging Phase III Data on Bezlotoxumab
04:40PM  Biotech Stocks Dive On Clinton's 'Price Gouging' Tweet at Investor's Business Daily
04:25PM  TRACON Skyrockets on Positive Choriocarcinoma Study Data
03:35PM  BioDelivery Up, Opioid Dependence Treatments in Focus
03:00PM  Why hiking drug prices is a 'terrible example': Pro
02:52PM  Major Indexes Still Mixed; Red Hat Up Ahead Of Earnings at Investor's Business Daily
02:24PM  Pill prices & politics
02:22PM  Are Biotech Stocks Overreacting to Clinton? at
01:28PM  25 Stock Picks from Goldman Sachs at The Wall Street Journal
12:45PM  The Next Biotech Giant Has Arrived
11:06AM  Regeneron Has Long Pipeline Products
09:07AM  Overview of Regeneron Pharmaceuticals
08:00AM  Regeneron Announces Agreement with BARDA for the Development of New Antibody Treatment for Ebola PR Newswire
Sep-20-15 08:42AM  3 Stocks Battling Heart Disease: 2 to Buy, 1 to Sell at Motley Fool
Sep-18-15 04:50PM  Allergan/Gedeon's Vraylar Gets FDA Nod for Mental Disorders
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company's trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has collaborations with Sanofi; license and collaboration agreement with Bayer HealthCare; and Avalanche Biotechnologies, Inc., as well as Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorSep 21Option Exercise57.113,000171,3303,000Sep 22 02:39 PM
BROWN MICHAEL SDirectorSep 21Sale551.553,0001,654,6500Sep 22 02:39 PM
BAKER CHARLES ADirectorSep 17Option Exercise18.615,00093,05014,000Sep 18 04:06 PM
BAKER CHARLES ADirectorSep 17Sale550.005,0002,750,0009,000Sep 18 04:06 PM
SCHLEIFER LEONARD SPresident & CEOSep 02Option Exercise402.697,2262,909,83849,313Sep 03 04:59 PM
LAROSA JOSEPH JSVP General Counsel and SecretSep 01Option Exercise59.201,68999,98916,756Sep 02 04:04 PM
Powchik PeterSVP Clinical Development & RegAug 14Sale573.3823,48513,465,86615,821Aug 17 04:01 PM
Powchik PeterSVP Clinical Development & RegAug 13Option Exercise117.3360,3617,082,07046,299Aug 17 04:01 PM
POON CHRISTINE ADirectorAug 12Sale564.1611263,186790Aug 12 04:45 PM
POON CHRISTINE ADirectorAug 11Option Exercise273.67470128,6251,125Aug 12 04:45 PM
GILMAN ALFRED GDirectorAug 06Option Exercise57.115,000285,55013,912Aug 07 06:15 PM
GILMAN ALFRED GDirectorAug 06Sale587.125,0002,935,6018,912Aug 07 06:15 PM
Terifay Robert JSVP CommercialAug 06Sale588.9713,4237,905,78123,293Aug 07 06:14 PM
Terifay Robert JSVP CommercialAug 05Option Exercise30.6332,500995,47552,529Aug 07 06:14 PM
Tessier-Lavigne MarcDirectorAug 05Option Exercise57.115,000285,5506,187Aug 05 08:55 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Option Exercise270.435,0001,352,1509,745Aug 05 08:58 PM
Landry Robert ESVP Finance & CFOAug 05Option Exercise272.704,0001,090,80011,099Aug 06 09:00 PM
Landry Robert ESVP Finance & CFOAug 05Sale592.844,0002,371,3507,099Aug 06 09:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Sale585.535,0002,927,6484,945Aug 05 08:58 PM
Tessier-Lavigne MarcDirectorAug 05Sale590.265,0002,951,2751,187Aug 05 08:55 PM
GOLDSTEIN JOSEPH LDirectorAug 04Sale586.002,0001,172,00014,000Aug 05 10:03 AM
GOLDSTEIN JOSEPH LDirectorJul 15Sale550.002,0001,100,00016,000Jul 15 04:09 PM
GOLDSTEIN JOSEPH LDirectorJun 22Sale526.852,0001,053,70018,000Jun 22 05:02 PM
SING GEORGE LDirectorMay 27Option Exercise19.695,00098,450117,772May 29 04:19 PM
SING GEORGE LDirectorMay 27Sale515.005,0002,575,000112,772May 29 04:19 PM
INGRAM ROBERT ALEXANDERDirectorMay 27Sale513.391,379707,9651,500May 27 04:02 PM
INGRAM ROBERT ALEXANDERDirectorMay 22Option Exercise293.536,6671,956,9656,667May 27 04:02 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Option Exercise174.0113,4642,342,90217,481May 26 04:31 PM
GOLDSTEIN JOSEPH LDirectorMay 22Sale514.284,0002,057,10020,000May 26 04:30 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Sale515.6013,0006,702,8004,481May 26 04:31 PM
BROWN MICHAEL SDirectorMay 15Option Exercise57.115,000285,5505,000May 18 04:50 PM
BROWN MICHAEL SDirectorMay 15Sale495.005,0002,475,0000May 18 04:50 PM
Landry Robert ESVP Finance & CFOApr 08Option Exercise272.7010,0002,727,00015,000Apr 09 04:03 PM
BAKER CHARLES ADirectorMar 25Option Exercise18.615,00093,05014,000Mar 26 04:20 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 25Option Exercise59.203,097183,34215,067Mar 26 04:21 PM
BAKER CHARLES ADirectorMar 25Sale454.965,0002,274,7859,000Mar 26 04:20 PM
Aberman Michael SSVP Strategy Investor RelationMar 24Sale478.994,8432,319,73812,498Mar 25 04:07 PM
Aberman Michael SSVP Strategy Investor RelationMar 18Sale465.003,4421,600,54222,498Mar 19 04:05 PM
Aberman Michael SSVP Strategy Investor RelationMar 17Option Exercise24.0011,398273,55229,998Mar 19 04:05 PM
Terifay Robert JSVP CommercialMar 17Sale451.0110,9934,957,90720,029Mar 18 06:03 PM
Terifay Robert JSVP CommercialMar 16Option Exercise30.6324,375746,60644,404Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Option Exercise59.2020,2811,200,63528,311Mar 17 04:57 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Sale450.0018,3118,239,95010,000Mar 17 04:57 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM